{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:13:08Z","timestamp":1789823588179,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-JC-YB-655"],"award-info":[{"award-number":["2023-JC-YB-655"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.heliyon.2024.e38488","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T02:32:59Z","timestamp":1727317979000},"page":"e38488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of molecular subtypes, prognostic status and immunotherapy response in cervical cancer based on angiogenic signature genes"],"prefix":"10.1016","volume":"10","author":[{"given":"Zhuo","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40001-023-01014-9","article-title":"siRNA-E6 sensitizes HPV-16-related cervical cancer through Oxaliplatin: an in vitro study on anti-cancer combination therapy","volume":"28","author":"Shiri Aghbash","year":"2023","journal-title":"European journal of medical research"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38488_bib2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2174\/0115734129270020231102081109","article-title":"Comprehensive review on analytical and bioanalytical methods for quantification of anti-angiogenic agents used in treatment of cervical cancer","volume":"19","author":"Nisha","year":"2023","journal-title":"Curr Pharm Anal"},{"key":"10.1016\/j.heliyon.2024.e38488_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: opportunity and challenge","volume":"471","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38488_bib4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","article-title":"Human papillomavirus and cervical cancer","volume":"40","author":"Okunade","year":"2020","journal-title":"J Obstet Gynaecol"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e38488_bib5","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38488_bib6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN guidelines(R) insights: cervical cancer, version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.32604\/Oncologie.2021.015154","article-title":"Nucleus detection on pap smear images for cervical cancer diagnosis: a review analysis","volume":"23","author":"Halim","year":"2021","journal-title":"Oncologie"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38488_bib8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/ijgc-2021-003001","article-title":"Global challenges of radiotherapy for the treatment of locally advanced cervical cancer","volume":"32","author":"Mayadev","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.heliyon.2024.e38488_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cancergen.2020.09.003","article-title":"Potential role of microRNAs in the treatment and diagnosis of cervical cancer","volume":"248\u2013249","author":"Shen","year":"2020","journal-title":"Cancer Genet."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e38488_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.canrad.2021.11.009","article-title":"Radiotherapy of cervical cancer","volume":"26","author":"Chargari","year":"2022","journal-title":"Cancer Radiother. : journal de la Societe francaise de radiotherapie oncologique."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38488_bib11","article-title":"Awareness of human papilloma virus and its association with cervical cancer among female university students: a study from United Arab Emirates","volume":"23","author":"Sundaram","year":"2021","journal-title":"Oncologie"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38488_bib12","article-title":"Challenges in the diagnosis and individualized treatment of cervical cancer","volume":"59","author":"Schubert","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e38488_bib13","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical cancer immunotherapy: facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38488_bib14","doi-asserted-by":"crossref","DOI":"10.32604\/oncologie.2022.024951","article-title":"Serum level of tumor-specific growth factor in patients with cervical cancer and its potential prognostic role","volume":"24","author":"Wu","year":"2022","journal-title":"Oncologie"},{"key":"10.1016\/j.heliyon.2024.e38488_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.945621","article-title":"Cervical cancer screening, treatment and prophylaxis in Brazil: current and future perspectives for cervical cancer elimination","volume":"9","author":"Correa","year":"2022","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s43046-021-00072-6","article-title":"Anti-angiogenesis in cancer therapeutics: the magic bullet","volume":"33","author":"Oguntade","year":"2021","journal-title":"J Egypt Natl Canc Inst"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010084","article-title":"Tumor angiogenesis and anti-angiogenic strategies for cancer treatment","volume":"9","author":"Teleanu","year":"2019","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38488_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073765","article-title":"Anti-angiogenic therapy: current challenges and future perspectives","volume":"22","author":"Lopes-Coelho","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38488_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38488_bib21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1517\/13543784.2013.812071","article-title":"Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment","volume":"22","author":"Wei","year":"2013","journal-title":"Expert Opin Inv Drug"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38488_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14712598.2016.1145208","article-title":"Bevacizumab for the treatment of cervical cancer","volume":"16","author":"Bizzarri","year":"2016","journal-title":"Expert Opin Biol Th"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38488_bib23","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38488_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38488_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization paths for cox's proportional hazards model via coordinate descent","volume":"39","author":"Simon","year":"2011","journal-title":"J Stat Softw"},{"issue":"30","key":"10.1016\/j.heliyon.2024.e38488_bib26","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","article-title":"Classification of triple-negative breast cancers based on Immunogenomic profiling","volume":"37","author":"He","year":"2018","journal-title":"Journal of experimental & clinical cancer research : CR"},{"key":"10.1016\/j.heliyon.2024.e38488_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.heliyon.2024.e38488_bib29","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e38488_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38488_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38488_bib33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/1573412918666220509032754","article-title":"A review on PCR and POC-PCR - a boon in the diagnosis of COVID-19","volume":"18","author":"Amuthalakshmi","year":"2022","journal-title":"Curr Pharm Anal"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38488_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7150\/ijbs.23230","article-title":"The role of TGF-beta\/SMAD4 signaling in cancer","volume":"14","author":"Zhao","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38488_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071586","article-title":"Role of FOXO transcription factors in cancer metabolism and angiogenesis","volume":"9","author":"Farhan","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38488_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082921","article-title":"G2M cell cycle pathway score as a prognostic biomarker of metastasis in estrogen receptor (ER)-Positive breast cancer","volume":"21","author":"Oshi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/cdd.2017.172","article-title":"Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM","volume":"25","author":"Engeland","year":"2018","journal-title":"Cell Death Differ."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e38488_bib38","first-page":"819","article-title":"IL-6 mediated JAK\/STAT3 signaling pathway in cancer patients with cachexia","volume":"66","author":"Eskiler","year":"2019","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.heliyon.2024.e38488_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.866014","article-title":"IL-6\/JAK\/STAT3 signaling in breast cancer metastasis: biology and treatment","volume":"12","author":"Manore","year":"2022","journal-title":"Frontiers in oncology"},{"key":"10.1016\/j.heliyon.2024.e38488_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101665","article-title":"Tregs are involved in VEGFA\/VASH1-related angiogenesis pathway in ovarian cancer","volume":"32","author":"Qiao","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.heliyon.2024.e38488_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.792385","article-title":"The renaissance of KRAS targeting in advanced non-small-cell lung cancer: new opportunities following old failures","volume":"11","author":"Ferrara","year":"2021","journal-title":"Frontiers in oncology"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e38488_bib42","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.21037\/atm-22-5184","article-title":"MiR-95-3p acts as a prognostic marker and promotes cervical cancer progression by targeting VCAM1","volume":"10","author":"Feng","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38488_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/sj.bjc.6603543","article-title":"Molecular profiling of cervical cancer progression","volume":"96","author":"Hagemann","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e38488_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166224","article-title":"CAP2 promotes gastric cancer metastasis by mediating the interaction between tumor cells and tumor-associated macrophages","volume":"133","author":"Zhang","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38488_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.498","article-title":"An epigenomic landscape of cervical intraepithelial neoplasia and cervical cancer using single-base resolution methylome and hydroxymethylome","volume":"11","author":"Han","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38488_bib46","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1007\/s13277-015-4312-3","article-title":"DLL4 as a predictor of pelvic lymph node metastasis and a novel prognostic biomarker in patients with early-stage cervical cancer","volume":"37","author":"Yang","year":"2016","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib47","article-title":"The role of Dll4\/Notch signaling in normal and pathological ocular angiogenesis: dll4 controls blood vessel sprouting and vessel remodeling in normal and pathological conditions","volume":"2018","author":"Lobov","year":"2018","journal-title":"J Ophthalmol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38488_bib48","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1158\/0008-5472.CAN-20-1996","article-title":"Delta-like ligand\u2013notch1 signaling is selectively modulated by HPV16 E6 to promote squamous cell proliferation and correlates with cervical cancer prognosis","volume":"81","author":"Khelil","year":"2021","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38488_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1659094","article-title":"Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors","volume":"8","author":"Yang","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2024.e38488_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.145119","article-title":"Identification of prognosis-related genes in the cervical cancer immune microenvironment","volume":"766","author":"Yang","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.heliyon.2024.e38488_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.782699","article-title":"ECM\u2013Receptor regulatory network and its prognostic role in colorectal cancer","volume":"12","author":"Nersisyan","year":"2021","journal-title":"Front. Genet."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38488_bib52","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s12276-020-0447-4","article-title":"Targeting focal adhesion kinase in cancer cells and the tumor microenvironment","volume":"52","author":"Murphy","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e38488_bib53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","article-title":"FAK signaling in human cancer as a target for therapeutics","volume":"146","author":"Lee","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib54","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1038\/s41467-021-23497-y","article-title":"Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum","volume":"12","author":"Cai","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38488_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127109","article-title":"Up-regulation of miR-21 is associated with cervicitis and human papillomavirus infection in cervical tissues","volume":"10","author":"Bumrungthai","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38488_bib56","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.3892\/or.2015.3931","article-title":"Overexpression of miR-21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN","volume":"33","author":"Xu","year":"2015","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38488_bib57","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3727\/096504017X15037506066252","article-title":"Overexpression of MicroRNA-34a-5p inhibits proliferation and promotes apoptosis of human cervical cancer cells by downregulation of bcl-2","volume":"26","author":"Wang","year":"2018","journal-title":"Oncol. Res."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38488_bib58","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.febslet.2008.03.057","article-title":"Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest","volume":"582","author":"Sun","year":"2008","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"key":"10.1016\/j.heliyon.2024.e38488_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.651222","article-title":"Therapies for chronic allograft rejection","volume":"12","author":"Kim","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38488_bib60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41581-023-00791-0","article-title":"Translating B cell immunology to the treatment of antibody-mediated allograft rejection","volume":"20","author":"Heeger","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e38488_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38488_bib62","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3892\/ol.2021.12809","article-title":"Cytochrome P450: implications for human breast cancer","volume":"22","author":"Luo","year":"2021","journal-title":"Oncol. Lett."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024145197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024145197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:50:40Z","timestamp":1789822240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024145197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":62,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2405844024145197"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38488","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of molecular subtypes, prognostic status and immunotherapy response in cervical cancer based on angiogenic signature genes","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e38488"}}